517 related articles for article (PubMed ID: 24231837)
1. A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women.
Gittelman M; Weiss H; Seidman L
J Urol; 2014 Apr; 191(4):1014-21. PubMed ID: 24231837
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
Staskin DR; Dmochowski RR; Sand PK; Macdiarmid SA; Caramelli KE; Thomas H; Hoel G
J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
[TBL] [Abstract][Full Text] [Related]
3. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
Malone-Lee J; Shaffu B; Anand C; Powell C
J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.
Sand PK; Davila GW; Lucente VR; Thomas H; Caramelli KE; Hoel G
Am J Obstet Gynecol; 2012 Feb; 206(2):168.e1-6. PubMed ID: 21963104
[TBL] [Abstract][Full Text] [Related]
6. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH;
Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Nelken RS; Ozel BZ; Leegant AR; Felix JC; Mishell DR
Menopause; 2011 Sep; 18(9):962-6. PubMed ID: 21532512
[TBL] [Abstract][Full Text] [Related]
8. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M;
Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence.
Dmochowski RR; Davila GW; Zinner NR; Gittelman MC; Saltzstein DR; Lyttle S; Sanders SW;
J Urol; 2002 Aug; 168(2):580-6. PubMed ID: 12131314
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial.
Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
Int J Urol; 2014 Jun; 21(6):586-93. PubMed ID: 24350662
[TBL] [Abstract][Full Text] [Related]
12. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial.
Wang AC; Chih SY; Chen MC
Urology; 2006 Nov; 68(5):999-1004. PubMed ID: 17113893
[TBL] [Abstract][Full Text] [Related]
13. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
Cartwright R; Srikrishna S; Cardozo L; Robinson D
BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389
[TBL] [Abstract][Full Text] [Related]
14. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
15. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
Nitti VW; Dmochowski R; Sand PK; Forst HT; Haag-Molkenteller C; Massow U; Wang J; Brodsky M; Bavendam T
J Urol; 2007 Dec; 178(6):2488-94. PubMed ID: 17937959
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study.
Goldfischer ER; Sand PK; Thomas H; Peters-Gee J
Neurourol Urodyn; 2015 Jan; 34(1):37-43. PubMed ID: 24133005
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
20. Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo.
Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
Low Urin Tract Symptoms; 2016 Sep; 8(3):150-8. PubMed ID: 27619779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]